{"id":"W2022184484","doi":"10.2174/1381612053382205","title":"Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions","year":2005,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Medicine; Trastuzumab; Myeloid leukemia; Targeted therapy; Bevacizumab; Chronic myelogenous leukemia; Clinical trial; Cancer; Bioinformatics; Breast cancer; Cancer research; Leukemia; Immunology; Biology; Internal medicine; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002077379,0.0007688085,0.001379059,0.00156985,0.0002647116,0.001253285,0.001038122,0.001212799,0.002995536],"category_scores_gemma":[0.001070911,0.0002530307,0.0003879746,0.001418308,0.0006595671,0.002384929,0.0004870907,0.001623868,0.001554805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008873258,"about_ca_system_score_gemma":0.0008413182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005468539,"about_ca_topic_score_gemma":0.00148985,"domain_scores_codex":[0.9996061,0.00009837106,0.00005788951,0.00006173382,0.0001400704,0.00003587181],"domain_scores_gemma":[0.9994276,0.0002838934,0.00008175858,0.00002339511,0.0001346609,0.00004873329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001648789,0.0002021577,0.0001809475,0.005791268,0.00005555218,0.0003164464,0.00009100844,0.0006557619,0.004866321,0.00784751,0.01021996,0.9696082],"study_design_scores_gemma":[0.0001336059,0.0008430966,0.0009482029,0.002721562,0.0001374857,0.002434986,0.0001547314,0.0004743391,0.005211288,0.005449777,0.9814585,0.0000324464],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007301158,0.9961649,0.0005290939,0.0008315687,0.0001183942,0.000009448545,0.00001217996,0.00001125633,0.001592977],"genre_scores_gemma":[0.002736533,0.9944566,0.0009954902,0.0005148511,0.0001906511,0.00001453555,0.00001769919,0.000003734762,0.001069805],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002995536,"threshold_uncertainty_score":0.01098639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2605662726175213,"score_gpt":0.5193172596919667,"score_spread":0.2587509870744454,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}